A Study of a Mutant-Selective Inhibitor, CGT6297, in Patients With Advanced Solid Tumors Harboring PIK3CA Mutations
This study tests an experimental medication called CGT6297 in adults with advanced solid tumors that have specific genetic changes known as PIK3CA mutations. The goal is to see how safe the drug is, how well the body handles it, and if it can help fight the cancer.
Adults with advanced solid tumors, such as certain types of breast or endometrial cancer, that contain PIK3CA gene changes may be eligible. Participants must have already tried other standard treatments and meet specific health and heart condition requirements.
Participants will receive the study medication, CGT6297, while doctors carefully monitor their health, side effects, and how the drug affects their cancer. This is a dose-escalation study, meaning researchers will test different amounts of the drug to find the safest and most effective dose.
This study is currently recruiting participants at locations in Arizona, California, and Colorado in the United States. Your care team will guide you through the exact steps and visit schedules at these centers.
- 1Evaluating a new experimental medication called CGT6297 for advanced solid tumors.
- 2Designed for adults whose cancers have specific PIK3CA gene mutations.
- 3Currently recruiting patients at select medical centers in the United States.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.